№ lp_2_3_40077
File format: docx
Character count: 14814
File size: 1117 KB
Year:
2019
Region / City:
Australia
Topic:
Invasive Pneumococcal Disease, Vaccination, Disease Surveillance
Document Type:
Surveillance Report
Organization / Institution:
Communicable Diseases Network Australia
Author:
Kate Pennington, Enhanced Invasive Pneumococcal Disease Surveillance Working Group
Target Audience:
Public Health Officials, Healthcare Providers
Period of Validity:
1 April 2019 – 30 June 2019
Approval Date:
Not specified
Date of Changes:
Not specified
Description:
Report on invasive pneumococcal disease incidence, vaccination impact, and seasonal variations across Australia for the second quarter of 2019.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2025
Region / city:
England
Topic:
Immunization
Document type:
Patient Group Direction (PGD)
Organization / institution:
UK Health Security Agency (UKHSA)
Author:
Suki Hunjunt, Professor Shamez Ladhani, David Green
Target audience:
Healthcare professionals involved in immunization
Period of validity:
From 5 January 2026 to 5 January 2029
Approval date:
5 January 2026
Amendment date:
2 June 2025, 16 December 2025
Description:
A document detailing the administration guidelines for the pneumococcal polysaccharide conjugate vaccine (PCV13, PCV15) for children under 2 years old in the UK.
Year:
2025
Region / city:
England
Topic:
Immunization
Document type:
Patient Group Direction (PGD)
Authoring body:
UK Health Security Agency (UKHSA)
Target audience:
Healthcare professionals involved in immunization programs
Period of validity:
17 December 2025 - 17 December 2028
Approval date:
9 December 2025
Review date:
17 July 2028
Expiry date:
17 December 2028
Publications gateway number:
GOV-16528
Reference number:
PPV23 PGD
Version:
5.00
Valid from:
1 September 2024
Review date:
1 September 2026
Expiry date:
1 March 2027
Vaccine:
23-valent pneumococcal polysaccharide vaccine (PPV23)
Programme:
National immunisation programme against pneumococcal disease
Target population:
Individuals aged 65 years and over and individuals aged 2 years and over in clinical risk groups
Geographical scope:
England
Legal framework:
Human Medicines Regulations 2012, Schedule 16 Part 2
Issuing organisation:
UK Health Security Agency
Developing body:
Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency
Authors:
Christina Wilson; Professor Shamez Ladhani; David Green
Approval status:
Ratified by the UKHSA Medicines Governance Committee
Document type:
Patient Group Direction
Year:
2021
Region / City:
Australia
Topic:
Pneumococcal vaccine submission
Document type:
Submission for listing on the National Immunisation Program
Author:
Merck Sharp & Dohme (Australia) Pty Ltd
Target audience:
Health professionals, regulatory bodies, policy makers
Period of validity:
Ongoing
Approval date:
16 July 2021 (FDA approval), 14 October 2021 (EMA recommendation)
Date of changes:
Not specified
Context:
A clinical submission for the inclusion of a 15-valent pneumococcal conjugate vaccine (PCV15) on the National Immunisation Program for adults at risk of pneumococcal disease.
Year:
2023
Region / city:
Australia
Subject:
Pneumococcal vaccine
Document type:
Submission
Organ / institution:
Therapeutic Goods Administration (TGA), Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Pfizer Australia Pty Ltd
Target audience:
Healthcare professionals, public health policymakers
Period of validity:
Ongoing
Approval date:
27 April 2023 (FDA approval)
Amendment date:
20 December 2022 (TGA submission)
Background:
This document presents the submission for the 20-valent pneumococcal conjugate vaccine to be listed on the National Immunisation Program in Australia for specific paediatric populations.
Year:
2023
Region / city:
Australia
Topic:
Pneumococcal vaccination
Document type:
Submission
Agency / organization:
Australian Technical Advisory Group on Immunisation (ATAGI)
Author:
Merck Sharp & Dohme (Australia) Pty Ltd
Target audience:
Healthcare professionals involved in immunization
Period of validity:
Not specified
Approval date:
Expected by 30 April 2023
Date of changes:
9 February 2023
Year:
2016
Region / City:
Australia
Theme:
Pneumococcal disease prevention
Document Type:
Submission
Organization / Institution:
Pfizer Australia Pty Ltd
Author:
Pfizer Australia Pty Ltd
Target Audience:
Healthcare professionals, policymakers, public health authorities
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2014
Region / City:
United States
Subject:
Pneumococcal immunization and health reminders
Document Type:
Installation and Setup Guide
Institution:
Department of Veterans Affairs
Author:
Not specified
Target Audience:
Healthcare professionals in the Veterans Affairs system
Validity Period:
Ongoing updates for system usage
Approval Date:
February 2014
Modification Date:
Not specified
Year:
2020
Region / City:
Australia
Topic:
Pneumococcal Vaccination Recommendations
Document Type:
Public Consultation
Organization:
Australian Technical Advisory Group on Immunisation (ATAGI)
Author:
Australian Technical Advisory Group on Immunisation (ATAGI)
Target Audience:
Healthcare professionals, general public, stakeholders in immunization policies
Period of Validity:
2020 and beyond
Approval Date:
Not specified
Date of Changes:
March 2020
Contextual Description:
Public consultation document outlining proposed changes to the recommended use of pneumococcal vaccines, aimed at improving vaccination guidelines and access for high-risk populations.
Document type:
Supplementary tables
Subject:
ICD-9-CM diagnostic codes for pneumococcal diseases and comorbidities
Disease categories:
Invasive pneumococcal disease (IPD), non-IPD pneumococcal infections, acute otitis media (AOM), otitis media with effusion (OME), AOM complications
Classification system:
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)
Content structure:
Disease type, clinical condition, ICD-9-CM code or code combinations, description
Clinical focus:
Pneumococcal infections and related complications
Additional dataset:
ICD-9-CM codes for prior comorbidities
Comorbidity categories:
Neurological, cardiovascular, lung, liver, kidney, metabolic, immunological conditions
Purpose:
Study cohort identification using diagnostic codes
Abbreviations:
IPD (Invasive Pneumococcal Diseases), PNI (Pneumococcal Infections), AOM (Acute Otitis Media), OME (Otitis Media with Effusion)
Year:
2023
Region / City:
Mauritius and Seychelles
Theme:
Environmental Management, Invasive Species, Project Evaluation
Document Type:
Management Response, Evaluation Report
Organization:
UNDP Mauritius and Seychelles CO
Author:
Seewajee Pandoo
Target Audience:
Project Management, Environmental Experts, Policy Makers
Period of Action:
June 2023
Date of Approval:
June 2023
Date of Updates:
N/A
Contextual description:
Management response to mid-term evaluation of the IAS Prevention, Control and Management project, outlining key actions and recommendations to address project implementation challenges.
Year:
2019–2024
Region / City:
European Union
Topic:
Invasive Alien Species Reporting
Document Type:
Guidelines
Institution:
European Commission
Author:
European Commission
Target Audience:
Member States of the European Union
Effective Period:
2019–2024
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2012
Region / City:
United Kingdom
Topic:
Radiology, Patient Safety, Invasive Procedures
Document Type:
Checklist, Audit
Organization / Institution:
The Royal College of Radiologists, National Patient Safety Agency
Author:
Edward Johnston, P Malcolm
Target Audience:
Radiologists, Radiographers, Nurses, Healthcare Assistants, Radiology Department Assistants
Period of Validity:
N/A
Approval Date:
Monday 21 May 2012
Last Reviewed:
Wednesday 26 June 2019
Context:
A checklist designed to ensure safety compliance for invasive radiological procedures, specifically focusing on peri-procedural safety checks and audit compliance.
Year:
2024
Region / City:
Not specified
Subject:
Pathology, Oncology
Document Type:
Protocol
Organization / Institution:
CAP (College of American Pathologists)
Author:
Uma G. Krishnamurti, MD, PhD; Kimberly H. Allison, MD; Patrick L. Fitzgibbons, MD, FCAP; James L. Connolly, MD
Target Audience:
Pathologists, Medical Institutions
Period of Validity:
March 2025
Approval Date:
Not specified
Date of Last Change:
June 2024
Version:
1.2.0.0
Protocol posting date:
March 2023
Document type:
Clinical pathology protocol
Medical field:
Breast pathology, oncology
Procedures covered:
Needle biopsy, fine needle aspiration, other biopsy procedures
Tumor types included:
Invasive breast carcinoma of any type, with or without ductal carcinoma in situ
Tumor types excluded:
Ductal carcinoma in situ without invasion, Paget disease without invasion, phyllodes tumor, lymphoma, sarcoma
Authors:
Patrick L. Fitzgibbons, MD, FCAP; James L. Connolly, MD
Organization:
College of American Pathologists
Accreditation status:
Recommended for clinical care, not required for accreditation
Intended use:
Reporting of biopsy specimens
Updates:
Optional reporting of largest invasive focus; revised lymphatic and/or vascular invasion terminology
Year:
2023
Region / city:
Canberra
Subject:
Neonatal respiratory support
Document type:
Clinical guideline
Author:
Canberra Health Services
Target audience:
Medical officers, nurses, midwives, physiotherapists, students under supervision
Date of approval:
Not specified
Date of changes:
Not specified
Clinical areas:
Neonatology, pediatric intensive care, respiratory therapy
Treatment procedures:
Invasive and non-invasive respiratory support, oxygen therapy, mechanical ventilation, physiotherapy
Medical equipment:
Ventilators, oxygen therapy devices, transcutaneous and end-tidal CO2 monitors, NAVA ventilators
Year:
2025-2026
Region / City:
Dallas, Texas
Subject:
Invasive Cardiovascular Technology
Document Type:
Program Information Packet
Institution:
Dallas College
Author:
Dallas College School of Health Sciences
Target Audience:
Prospective Students
Period of Validity:
May 2026 Program Application
Approval Date:
Not specified
Date of Modifications:
Not specified
Year:
2025
Region / City:
Massachusetts
Topic:
Invasive plant management, Herbicide application
Document Type:
Specification
Organization / Institution:
MassDOT (Massachusetts Department of Transportation)
Author:
MassDOT Landscape Design Section
Target Audience:
Contractors, Applicators
Validity Period:
As long as contract is in effect
Approval Date:
2025-03-01
Date of Changes:
None specified
Year:
2019–2024
Region / city:
European Union
Subject:
Invasive Alien Species Reporting
Document Type:
Guideline
Institution:
European Commission
Target Audience:
Member States, Environmental Authorities
Approval Date:
Not specified
Date of Changes:
Not specified
Note:
Year
Theme:
Surgical Safety, Perioperative Practices
Document Type:
Policy
Organization / Institution:
[Insert name of facility]
Target Audience:
Perioperative Team